» Articles » PMID: 31736740

Systemic Immune Dyshomeostasis Model and Pathways in Alzheimer's Disease

Overview
Specialty Geriatrics
Date 2019 Nov 19
PMID 31736740
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) still remains an enigma for researchers and clinicians. The onset of AD is insidious, gradually progressive and multifactorial. The recent accumulated scientific evidences suggests that the pathological changes resemble the autoimmune-driven self-sustaining inflammatory process as a result of prolonged oxidative stress and immune dyshomeostasis. Apart from aging, during life span various other factors-mainly environmental, lifestyle, chronic stress, polymicrobial infections and neuroendocrine functions-affect the immune system. Here, we provide crosstalk among "trigger insults/inflammatory stimulus" i.e., polymicrobial infection, chronic stress, pro-inflammatory diet and cholinergic signaling to put forward a "Systemic Immune Dyshomeostasis" model as to connect the events leading to AD development and progression. Our model implicates altered cholinergic signaling and suggests pathological stages with various modifiable risk factors and triggers at different chronological age and stage of cognitive decline. The search of specific autoantibodies for AD which may serve as the suitable blood/CSF biomarkers should be actively pursued for the early diagnosis of AD. The preventive and therapeutic strategies should be directed towards maintaining the normal functioning of the immune system throughout the life span and specific modulation of the immune responses in the brain depending on the stage of changes in brain.

Citing Articles

pyPAGE: A framework for Addressing biases in gene-set enrichment analysis-A case study on Alzheimer's disease.

Bakulin A, Teyssier N, Kampmann M, Khoroshkin M, Goodarzi H PLoS Comput Biol. 2024; 20(9):e1012346.

PMID: 39236079 PMC: 11421795. DOI: 10.1371/journal.pcbi.1012346.


Vascular Parkinsonism-A Revisit.

Gupta M Ann Indian Acad Neurol. 2024; 27(1):3-4.

PMID: 38495235 PMC: 10941897. DOI: 10.4103/aian.aian_234_23.


Role of Cholinergic Signaling in Alzheimer's Disease.

Chen Z, Huang J, Yang S, Hong F Molecules. 2022; 27(6).

PMID: 35335180 PMC: 8949236. DOI: 10.3390/molecules27061816.


Systematic Review of Different Neuroimaging Correlates in Mild Cognitive Impairment and Alzheimer's Disease.

Talwar P, Kushwaha S, Chaturvedi M, Mahajan V Clin Neuroradiol. 2021; 31(4):953-967.

PMID: 34297137 DOI: 10.1007/s00062-021-01057-7.


Neuroinflammation in Alzheimer's Disease.

Onyango I, Jauregui G, carna M, Bennett Jr J, Stokin G Biomedicines. 2021; 9(5).

PMID: 34067173 PMC: 8150909. DOI: 10.3390/biomedicines9050524.


References
1.
Suh S, Aoyama K, Matsumori Y, Liu J, Swanson R . Pyruvate administered after severe hypoglycemia reduces neuronal death and cognitive impairment. Diabetes. 2005; 54(5):1452-8. DOI: 10.2337/diabetes.54.5.1452. View

2.
Amenta F, Parnetti L, Gallai V, Wallin A . Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches?. Mech Ageing Dev. 2001; 122(16):2025-40. DOI: 10.1016/s0047-6374(01)00310-4. View

3.
Ning S, Jorfi M . Beyond the sleep-amyloid interactions in Alzheimer's disease pathogenesis. J Neurophysiol. 2019; 122(1):1-4. DOI: 10.1152/jn.00118.2019. View

4.
Wang H, Wahlberg M, Karp A, Winblad B, Fratiglioni L . Psychosocial stress at work is associated with increased dementia risk in late life. Alzheimers Dement. 2012; 8(2):114-20. DOI: 10.1016/j.jalz.2011.03.001. View

5.
de Leon M, Li Y, Okamura N, Tsui W, Saint-Louis L, Glodzik L . Cerebrospinal Fluid Clearance in Alzheimer Disease Measured with Dynamic PET. J Nucl Med. 2017; 58(9):1471-1476. PMC: 5577629. DOI: 10.2967/jnumed.116.187211. View